Geron (NASDAQ: GERN)
Geron Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Geron Company Info
Geron Corp. operates as a biotechnology company. It develops a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies. The firm develops therapeutic products for oncology. The company was founded by Michael D. West on November 28, 1990 and is headquartered in Foster City, CA.
News & Analysis
Why Geron Stock Crept Higher Today
Why Geron Stock Is Plummeting Today
Is Geron Stock a Buy Following Its First New Drug Approval?
Find out if the high-flying biotech stock can keep on climbing higher.
Why Shares of Geron Are Up 30% This Week
The company's CEO was scheduled to speak at a virtual conference on Thursday.
2 Top Healthcare Stocks to Buy Right Now
One has a breakout drug, the other a nice-sized moat.
These 2 Nasdaq Biotechs Are Making Big Moves Wednesday
The binary nature of biotech investing is making itself obvious from recent study results.
Why Geron's Shares Rose 14.78% on Wednesday
The company said it expects to submit a new drug application for its lead candidate early next year.
Why Geron Stock Is Soaring Today
Investors are reacting positively to the company's Q1 update.
Valuation
Podcast Episodes
Earnings Transcripts
Geron (GERN) Q4 2024 Earnings Call Transcript
GERN earnings call for the period ending December 31, 2024.
Geron (GERN) Q3 2024 Earnings Call Transcript
GERN earnings call for the period ending September 30, 2024.
Geron (GERN) Q2 2024 Earnings Call Transcript
GERN earnings call for the period ending June 30, 2024.
Geron (GERN) Q1 2024 Earnings Call Transcript
GERN earnings call for the period ending March 31, 2024.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.